In particular this latter subset of patients, compared to MM patients who received one line of therapy, displayed lower CD4+ lymphocytes (26.2 ± 10.4% vs 30.5 ± 10.7%, p=0.0029, Figure 2B) and higher total T cells (52.7 ± 13.1% vs 41.1 ± 12.2%, p<0.0001, Figure 2A), CD8+ lymphocytes (52.7 ± 13.1% vs 41.1 ± 12.2%, p<0.0001, Figure 2C), CD8+/DR+ lymphocytes (14.1 ± 14.8% vs 7.9 ± 10.6%, p=0.0008, Figure 2D), CD3+/CD57+ lymphocytes (21.1 ± 12.7% vs 16.4 ± 10.7%, p=0.0018, Figure 2E) and Tγδ cells (5.7 ± 6.0% vs 3.0 ± 3.0%, p<0.0001, Figure 2F). Here, CD4 is linked to Miyoshi myopathy.